

Special Issue

Progress in Immunopharmacy

Message from the Guest Editors

This Special Issue, "Progress in Immunopharmacy", aims to explore recent advancements and emerging trends in the field of immunopharmacy and immunopharmacology, encompassing the study of immune system-targeting pharmacological interventions, including immunomodulatory drugs, vaccines, and immunotherapies. It seeks to provide a platform for researchers to showcase their innovative research findings, methodologies, and discoveries related to immunopharmacy and immunopharmacology. The topics of interest may include but are not limited to the development of novel immunotherapeutic agents, immunopharmacological mechanisms, drug interactions with the immune system, personalized immunopharmacotherapy approaches, and clinical immunopharmacy applications in various disease settings. By highlighting the latest progress in immunopharmacy, this Special Issue aims to stimulate further research, foster collaboration, and contribute to the advancement of pharmacotherapy tailored to immune response modulation for improved health outcomes.

Guest Editors

Dr. Po-Jen Chen

Department of Medical Research, E-Da Hospital, Kaohsiung 824410, Taiwan

Dr. Shun-Hua Chen

School of Nursing, Fooyin University, Kaohsiung 831301, Taiwan

Deadline for manuscript submissions

closed (31 August 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9

CiteScore 6.8

Indexed in PubMed



mdpi.com/si/206416

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](http://mdpi.com/journal/biomedicines)

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

